Completed PHASE3 INTERVENTIONAL 3-arm NCT00401362

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness

Sponsor: Bausch Health Americas, Inc.

Conditions Advanced Illness Patients With Opioid Induced Constipation

Interventions SC Methylnaltrexone SC Placebo

Updated 8 times since 2017 Last updated: Nov 21, 2019 Started: Feb 28, 2003 Primary completion: Feb 28, 2005 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Advanced Illness Patients With Opioid Induced Constipation, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 8 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2019 — Dec 2019 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch Health Americas, Inc.
Pfizer

Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tarrytown, United States